BioMarin gains up to 20% Yuviwel royalty rights in settlement with Ascendis
BioMarin (NASDAQ:BMRN) entered into binding global settlement terms with Ascendis Pharma A/S to resolve patent disputes involving Yuviwel, including a U.S. International Trade Commission investigation and litigation in multiple countries.










